Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Fine analysis of atypical circulating tumor cells in metastatic breast cancer patients reveals subsets with different prognostic values

Alexia Lopresti, Laurys Boudin, Pascal Finetti, Séverine Garnier, Anaïs Aulas, Maria-Lucia Liberatoscioli, Arnaud Guille, Quentin Dacosta, Olivier Cabaud, Jihane Pakradouni, Anthony Goncalves, Daniel Birnbaum, François Bertucci, Emilie Mamessier, Claire Acquaviva
doi: https://doi.org/10.1101/2020.09.29.20203653
Alexia Lopresti
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurys Boudin
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Finetti
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Séverine Garnier
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anaïs Aulas
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria-Lucia Liberatoscioli
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnaud Guille
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quentin Dacosta
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Cabaud
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jihane Pakradouni
2Department of Clinical Research and Innovation, Sponsor Unit, Institut Paoli-Calmettes, Mar-seille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Goncalves
3Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Birnbaum
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Bertucci
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
3Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilie Mamessier
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: emilie.mamessier@inserm.fr
Claire Acquaviva
1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose Circulating tumor cells (CTCs) have a tremendous potential for diagnosis and treatment of breast cancer patients. Here, we performed a unique analysis of all atypical circulating cells isolated with a filtration-based technology from metastatic breast cancer (mBC) patients.

Patients and methods The PERMED-01 study enrolled patients with mBC, refractory to systemic therapy, and with an accessible lesion to biopsy. We analyzed atypical circulating cells isolated from patients’ blood at the time of inclusion using Screencell® Cyto device. For 23 out of 91 analyzed patients, this was completed by advanced immunofluorescence staining of atypical circulating cells. Subsets cut-offs were established using a two-component Gaussian finite Mixture Model, and evaluated for correlation with clinico-pathological data, including progression-free survival (PFS) and overall survival (OS).

Results Three subsets of atypical circulating cells, absent from controls (n=7), were observed in cancer patients (n=91): isolated (iCTCs), Clusters (CTM), and Giant CTCs (gCTCs). CTCs’ median number was 8.33 per mL. Co-expression of stem and drug resistance markers was associated with intermediate epithelial to mesenchymal transition phenotype in CTM and gCTCs, but not in iCTCs. Presence of gCTC was associated with shorter PFS and OS. Concerning PFS, assigning an immunofluorescence-based Epithelial to Mesenchymal status improved their prognostic value.

Conclusion This study brings to light the diversity of CTCs in mBC patients and their specific molecular profiles regarding epithelial to mesenchymal transition, stemness and drug resistance status. It also highlights the involvement of an atypical circulating cell subset, the gCTCs, as a prognostic factor for PFS and OS.

Competing Interest Statement

AG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche.

Clinical Trial

NCT02342158

Funding Statement

This work has been supported by Inserm, Institut Paoli-Calmettes (SIRIC INCa-DGOS-Inserm 6038), and grants from the Ligue Nationale Contre Le Cancer (EL2016.LNCC/DaB, EL2019.LNCC/FB), Association Ruban Rose, and Foundation Groupe EDF. AL was supported by the fellowship DOC4 from the Fondation ARC (DOC20180507420). AA was supported by a postdoctoral fellowship from the Fondation ARC (PDF20180507565) and the Fondation de France (00107936). Conflict of Interest: AG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

National ethics committee (CPP Sud-Mediterranee) registered as identifier NCT02342158 at the ClinicalTrials.gov platform

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of Interest: AG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche

  • Funding support: This work has been supported by Inserm, Institut Paoli-Calmettes (SIRIC INCa-DGOS-Inserm 6038), and grants from the Ligue Nationale Contre Le Cancer (EL2016.LNCC/DaB, EL2019.LNCC/FB), Association Ruban Rose, and Foundation Groupe EDF. AL was supported by the fellowship DOC4 from the Fondation ARC (n°DOC20180507420). AA was supported by a postdoctoral fellowship from the Fondation ARC (n°PDF20180507565) and the Fondation de France (n°00107936).

Data Availability

Data will be available on request

  • Abbreviations

    mBC
    metastatic breast cancer
    CTCs
    Circulating Tumor Cells
    iCTCs
    isolated Circulating Tumor Cells
    gCTC
    giant Circulating Tumor Cells
    EM status
    Epithelial to Mesenchymal status
    EMT
    Epithelial to Mesenchymal Transition
    PFS
    Progression free survival
    OS
    Overall survival
    CTM
    Circulating tumor microemboli
    TN
    Triple Negative
    TAM
    Tumor Associated Macrophage
    CAMLs
    Cancer-Associated Macrophage-Like cells
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted September 29, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Fine analysis of atypical circulating tumor cells in metastatic breast cancer patients reveals subsets with different prognostic values
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Fine analysis of atypical circulating tumor cells in metastatic breast cancer patients reveals subsets with different prognostic values
    Alexia Lopresti, Laurys Boudin, Pascal Finetti, Séverine Garnier, Anaïs Aulas, Maria-Lucia Liberatoscioli, Arnaud Guille, Quentin Dacosta, Olivier Cabaud, Jihane Pakradouni, Anthony Goncalves, Daniel Birnbaum, François Bertucci, Emilie Mamessier, Claire Acquaviva
    medRxiv 2020.09.29.20203653; doi: https://doi.org/10.1101/2020.09.29.20203653
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    Fine analysis of atypical circulating tumor cells in metastatic breast cancer patients reveals subsets with different prognostic values
    Alexia Lopresti, Laurys Boudin, Pascal Finetti, Séverine Garnier, Anaïs Aulas, Maria-Lucia Liberatoscioli, Arnaud Guille, Quentin Dacosta, Olivier Cabaud, Jihane Pakradouni, Anthony Goncalves, Daniel Birnbaum, François Bertucci, Emilie Mamessier, Claire Acquaviva
    medRxiv 2020.09.29.20203653; doi: https://doi.org/10.1101/2020.09.29.20203653

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (76)
    • Allergy and Immunology (198)
    • Anesthesia (54)
    • Cardiovascular Medicine (492)
    • Dentistry and Oral Medicine (90)
    • Dermatology (56)
    • Emergency Medicine (169)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (213)
    • Epidemiology (5706)
    • Forensic Medicine (3)
    • Gastroenterology (217)
    • Genetic and Genomic Medicine (870)
    • Geriatric Medicine (88)
    • Health Economics (232)
    • Health Informatics (763)
    • Health Policy (394)
    • Health Systems and Quality Improvement (254)
    • Hematology (105)
    • HIV/AIDS (182)
    • Infectious Diseases (except HIV/AIDS) (6498)
    • Intensive Care and Critical Care Medicine (391)
    • Medical Education (118)
    • Medical Ethics (28)
    • Nephrology (93)
    • Neurology (850)
    • Nursing (44)
    • Nutrition (141)
    • Obstetrics and Gynecology (163)
    • Occupational and Environmental Health (263)
    • Oncology (515)
    • Ophthalmology (163)
    • Orthopedics (44)
    • Otolaryngology (107)
    • Pain Medicine (48)
    • Palliative Medicine (21)
    • Pathology (149)
    • Pediatrics (251)
    • Pharmacology and Therapeutics (147)
    • Primary Care Research (114)
    • Psychiatry and Clinical Psychology (972)
    • Public and Global Health (2237)
    • Radiology and Imaging (377)
    • Rehabilitation Medicine and Physical Therapy (174)
    • Respiratory Medicine (313)
    • Rheumatology (109)
    • Sexual and Reproductive Health (81)
    • Sports Medicine (82)
    • Surgery (118)
    • Toxicology (25)
    • Transplantation (34)
    • Urology (42)